To conquer the tumor-penetrating problem that precludes CAR-T immunotherapy, Zhang et al. developed a novel murine CAR macrophage harboring mouse CD147 transmembrane and intracellular regions, which enables macrophages to cross the extracellular matrix (ECM) to target HER2+ cancer cells [23]. Here, ERBB2 is linked to cancer.